Skip to main content
. Author manuscript; available in PMC: 2015 Sep 23.
Published in final edited form as: Integr Cancer Sci Ther. 2015 Aug 4;2(4):192–200. doi: 10.15761/icst.1000139

Figure 5.

Figure 5

P2Y1 Receptor blockade or NM23 antagonist significantly suppresses tumor formation in vivo. Once MDA-MB-231Luc+ primary tumors in SCID mice attained a volume of 100–200 mm3, the osmotic pumps were implanted subcutaneously (back scruff) to deliver 200 μM MRS2179 or endostatin (pump internal volume, 100 μl) continuously delivered drugs at the rate of 0.11μl/hr for 30 days (26.4 pg/gram/day for both MRS 2179 and endostatin). EA was administrated in drinking water at 120 μg/ml (~34 μg/gram/day). Tumor volume and tumor bioluminescence were measured weekly to evaluate the effect of antitumor inhibitors (n=8 mice/group), and the images represent inhibition of primary tumor at 16 weeks compared to the control group (no treatment) at week 16 by bioluminescent activity.